Drug therapy for esophageal and gastric fundus varices in liver cirrhosis

doi:10.16139/j.1007-9610.2021.03.005

Abstract

CLC Number:

R657.34

HU Mingli, WANG Qixia, MA Xiong. Drug therapy for esophageal and gastric fundus varices in liver cirrhosis[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 203-207.

References 32

[1]	Alqahtani SA, Jang S. Pathophysiology and management of variceal bleeding[J]. Drugs, 2021, 81(6):647-667. doi: 10.1007/s40265-021-01493-2 URL
[2]	Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11):1680-1704. doi: 10.1136/gutjnl-2015-309262 pmid: 25887380
[3]	de Franchis R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: report of the Baveno Ⅵ Consensus Workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3):743-752. doi: 10.1016/j.jhep.2015.05.022 pmid: 26047908
[4]	徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 实用肝脏病杂志, 2016, 19(5):641-656.
[5]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2):406-460. doi: 10.1016/j.jhep.2018.03.024 URL
[6]	Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013, 62(11):1634-1641. doi: 10.1136/gutjnl-2012-304038 pmid: 23250049
[7]	杨连粤, 白雪莉. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(12):1241-1247.
[8]	Zanetto A, Garcia-Tsao G. Management of acute variceal hemorrhage[J]. F1000Res, 2019, 8:F1000 Faculty Rev-966. doi: 10.12688/f1000research.19590.2 URL
[9]	Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review[J]. Aliment Pharmacol Ther, 2011, 34(5):509-518. doi: 10.1111/j.1365-2036.2011.04746.x URL
[10]	Tandon P, Abraldes JG, Keough A, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics[J]. Clin Gastroenterol Hepatol, 2015, 13(6):1189-1196.e2. doi: 10.1016/j.cgh.2014.11.019 URL
[11]	Ready JB, Robertson AD, Goff JS, et al. Assessment of the risk of bleeding from esophageal varices by conti-nuous monitoring of portal pressure[J]. Gastroenterology, 1991, 100(5 Pt 1):1403-1410. pmid: 2013385
[12]	D′Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review[J]. Hepatology, 1995, 22(1):332-354.
[13]	Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin for acute esophageal variceal hemorrhage[J]. Aliment Pharmacol Ther, 2003, 17(1):53-64.
[14]	Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension[J]. Aliment Pharmacol Ther, 2003, 18(4):375-386. doi: 10.1046/j.1365-2036.2003.01657.x URL
[15]	Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds[J]. Aliment Pharmacol Ther, 2012, 35(11):1267-1278. doi: 10.1111/j.1365-2036.2012.05088.x URL
[16]	Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage[J]. Hepatology, 2014, 60(3):954-963. doi: 10.1002/hep.27006 URL
[17]	Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: a new view of an old problem[J]. Clin Gastroenterol Hepatol, 2015, 13(12):2109-2117. doi: 10.1016/j.cgh.2015.07.012 URL
[18]	Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis[J]. Hepatology, 2017, 66(4):1219-1231. doi: 10.1002/hep.29267 pmid: 28543862
[19]	Turco L, Villanueva C, La Mura V, et al. A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis[J]. J Hepatol, 2017, 66(1 Supplement):S103-S104.
[20]	Sersté T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology, 2010, 52(3):1017-1022. doi: 10.1002/hep.23775 URL
[21]	Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Gastroenterology, 2014, 146(7):1680-1690.e1. doi: 10.1053/j.gastro.2014.03.005 pmid: 24631577
[22]	Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices[J]. Aliment Pharmacol Ther, 2010, 32(7):859-871. doi: 10.1111/j.1365-2036.2010.04418.x URL
[23]	Puente A, Hernández-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an upda-ted systematic review[J]. Liver Int, 2014, 34(6):823-833. doi: 10.1111/liv.12452 URL
[24]	Bunchorntavakul C, Reddy KR. Pharmacologic management of portal hypertension[J]. Clin Liver Dis, 2019, 23(4):713-736. doi: S1089-3261(19)30043-1 pmid: 31563219
[25]	Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J]. Gastroenterology, 2004, 126(3):749-755. doi: 10.1053/j.gastro.2003.12.007 URL
[26]	Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analy-sis[J]. Clin Gastroenterol Hepatol, 2017, 15(10):1521-1530.e8. doi: 10.1016/j.cgh.2017.04.039 URL
[27]	Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J]. Gastroenterology, 2016, 150(5):1160-1170.e3. doi: S0016-5085(16)00043-3 pmid: 26774179
[28]	Tranah TH, Edwards LA, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70(5):982-994. doi: 10.1136/gutjnl-2020-320786 URL
[29]	Trebicka J, Bork P, Krag A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):167-180. doi: 10.1038/s41575-020-00376-3 pmid: 33257833
[30]	Gupta N, Kumar A, Sharma P, et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial[J]. Liver Int, 2013, 33(8):1148-1157. doi: 10.1111/liv.12172 URL
[31]	徐小元, 丁惠国, 李文刚, 等. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10):1847-1863.
[32]	Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28(3):450-455. doi: 10.1111/jgh.12070 URL

Drug therapy for esophageal and gastric fundus varices in liver cirrhosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 32

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	ZHANG Mengyin, CHEN Ping, YUAN Xiaoqin, CAI Boer, WU Yunlin. Clinical study on endoscopic injection of tissue adhesive with hardener in treatment of gastric varices and follow-up [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 443-447.
[2]	CHEN Xiaojuan, ZHANG Wen, CAI Yu. Transcatheter splenic artery embolization for pancreatic sinistral portal hypertension with gastrointestinal blee-ding: a case report [J]. Journal of Surgery Concepts & Practice, 2022, 27(04): 359-362.
[3]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 139-144.
[4]	SUN Longci, ZHANG Bin. Surgical treatment of esophagogastric varices from cavernous transformation of portal vein: one case report [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 226-230.
[5]	CUI Ran, YE Lunhe, WANG Xujing, WANG Yongkun, ZHANG Qiqi, WANG Kaijing, WANG Ming, DAI Chenxin, YANG Ludi, DONG Chunxiu, CHEN Bo. Short-term clinical outcome of laparoscopic splenectomy combined with peripheral cardia disconnection in treatment of portal hypertension in liver cirrhosis [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 221-225.
[6]	YANG Tao, YIN Jikai, LU Jianguo. Prospect of laparoscopic surgery in treatment of portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 217-220.
[7]	CHEN Wei, BU Junfeng. Evaluation of liver function in portal hypertension during perioperative stage [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 212-216.
[8]	FAN Xinxin, WU Xingjiang, HE Changsheng. Clinical value of TIPS in treatment of portal hypertension with esophageal and gastric fundus variceal hemorrhage [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 208-211.
[9]	ZHANG Bin, WU Zhiyong. Individualized treatment of esophagogastric variceal hemorrhage in portal hypertension and selection of surgical procedure [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 185-188.
[10]	LI Tao, CHEN Hao. Liver transplantation in treatment of cirrhotic portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 189-194.
[11]	LUO Meng, LI Hongjie, ZHENG Lei. Study on pathogenesis of cirrhotic portal hypertension: current status [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 195-198.
[12]	ZENG Ning, FANG Chihua. Use of digital technology and intelligence in diagnosis and treatment for patients with portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 199-202.